466 related articles for article (PubMed ID: 20305700)
21. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.
Keating GM
Drugs; 2011 Aug; 71(12):1623-47. PubMed ID: 21861545
[TBL] [Abstract][Full Text] [Related]
22. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
Stiff P; Micallef I; McCarthy P; Magalhaes-Silverman M; Weisdorf D; Territo M; Badel K; Calandra G
Biol Blood Marrow Transplant; 2009 Feb; 15(2):249-56. PubMed ID: 19167685
[TBL] [Abstract][Full Text] [Related]
23. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
24. Plerixafor in poor stem cell mobilizers: the Belgian Compassionate Use Program.
Selleslag D; Dierickx D; Breems DA; Huynh P; Van De Velde A; Meers S; Brouwer E; Mertens A
Acta Clin Belg; 2011; 66(3):200-4. PubMed ID: 21837928
[TBL] [Abstract][Full Text] [Related]
25. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
Hartmann T; Hübel K; Monsef I; Engert A; Skoetz N
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010615. PubMed ID: 26484982
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy and Safety of Plerixafor Combined with G-CSF for Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization in Lymphoma Patients].
Guan FS; He DH; Li Y; Zhang Y; Zheng GF; Zhu YY; He JS; Zhang EF; Cai Z; Zhao Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1056-1060. PubMed ID: 37551477
[TBL] [Abstract][Full Text] [Related]
27. Autologous Stem Cell Mobilization in the Age of Plerixafor.
Cooper DL; Medoff E; Patel N; Baker J; Pratt K; Foss F; Seropian SE; Perreault S; Wu Y
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):411-6. PubMed ID: 27245311
[TBL] [Abstract][Full Text] [Related]
28. Plerixafor use in patients with previous mobilization failure: A multicenter experience.
Tekgündüz E; Altuntaş F; Sıvgın S; Akı SZ; Dönmez A; Topçuoğlu P; Yıldırım R; Baysal NA; Ayyıldız E; Yüksel MK; Sarı I; Tombuloğlu M; Unal A; Ilhan O
Transfus Apher Sci; 2012 Aug; 47(1):77-80. PubMed ID: 22609192
[TBL] [Abstract][Full Text] [Related]
29. A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
Mina R; Petrucci MT; Bonello F; Bongarzoni V; Saccardi R; Bertuglia G; Mengarelli A; Spadaro A; Lisi C; Curci P; Lemoli RM; Ballanti S; Floris R; Cupelli L; Tosi P; Olivieri A; Rota-Scalabrini D; Cangialosi C; Nozzoli C; Anaclerico B; Fazio F; Bruno B; Mancuso K; Corradini P; Milone G; Boccadoro M
Haematologica; 2024 May; 109(5):1525-1534. PubMed ID: 37981892
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.
Jantunen E; Kuittinen T; Mahlamäki E; Pyörälä M; Mäntymaa P; Nousiainen T
Eur J Haematol; 2011 Apr; 86(4):299-304. PubMed ID: 21198864
[TBL] [Abstract][Full Text] [Related]
31. Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts.
Holmberg LA; Linenberger M; Connelly-Smith L
Transplant Cell Ther; 2022 Nov; 28(11):754-759. PubMed ID: 36002104
[TBL] [Abstract][Full Text] [Related]
32. Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program.
Shaughnessy P; Uberti J; Devine S; Maziarz RT; Vose J; Micallef I; Jacobsen E; McCarty J; Stiff P; Artz A; Ball ED; Berryman R; Dugan M; Joyce R; Hsu FJ; Johns D; McSweeney P
Bone Marrow Transplant; 2013 Jun; 48(6):777-81. PubMed ID: 23178544
[TBL] [Abstract][Full Text] [Related]
33. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
34. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.
Micallef IN; Stiff PJ; DiPersio JF; Maziarz RT; McCarty JM; Bridger G; Calandra G
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1578-86. PubMed ID: 19896082
[TBL] [Abstract][Full Text] [Related]
35. Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution.
Cooper DL; Pratt K; Baker J; Medoff E; Conkling-Walsh A; Foss F; Snyder E; Yen W; Seropian SE
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):267-72. PubMed ID: 21658654
[TBL] [Abstract][Full Text] [Related]
36. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
Farina L; Spina F; Guidetti A; Longoni P; Ravagnani F; Dodero A; Montefusco V; Carlo-Stella C; Corradini P
Leuk Lymphoma; 2014 Feb; 55(2):331-6. PubMed ID: 23656194
[TBL] [Abstract][Full Text] [Related]
37. Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.
Micallef IN; Stiff PJ; Nademanee AP; Maziarz RT; Horwitz ME; Stadtmauer EA; Kaufman JL; McCarty JM; Vargo R; Cheverton PD; Struijs M; Bolwell B; DiPersio JF
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1187-1195. PubMed ID: 29410180
[TBL] [Abstract][Full Text] [Related]
38. Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.
Andreola G; Babic A; Rabascio C; Negri M; Martinelli G; Laszlo D
Eur J Haematol; 2012 Feb; 88(2):154-8. PubMed ID: 21992403
[TBL] [Abstract][Full Text] [Related]
39. Stimulation of adrenergic activity by desipramine enhances hematopoietic stem and progenitor cell mobilization along with G-CSF in multiple myeloma: A pilot study.
Shastri A; Budhathoki A; Barta SK; Kornblum N; Derman O; Battini R; Raghupathy R; Verma AK; Frenette PS; Braunschweig I; Janakiram M
Am J Hematol; 2017 Oct; 92(10):1047-1051. PubMed ID: 28675459
[TBL] [Abstract][Full Text] [Related]
40. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF.
D'Addio A; Curti A; Worel N; Douglas K; Motta MR; Rizzi S; Dan E; Taioli S; Giudice V; Agis H; Kopetzky G; Soutar R; Casadei B; Baccarani M; Lemoli RM
Bone Marrow Transplant; 2011 Mar; 46(3):356-63. PubMed ID: 20577218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
